Asensus Surgical Announces Sale of Senhance Robotic System
August 04 2022 - 6:55AM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to pioneer a new era of Performance-Guided Surgery™,
today announced that a Senhance® Surgical System was sold to the
Company’s distribution partner, and will be placed in a hospital in
the Commonwealth of Independent States (CIS) region.
“We are excited to be partnering with yet another institution to
initiate a Senhance program to deliver better patient outcomes,”
said Anthony Fernando, Asensus Surgical President and CEO. “With
the combination of unique instrumentation, including 3mm and
articulation, advanced safety features such as haptic feedback, and
the industry's only intelligent Artificial Intelligence platform,
Senhance provides the opportunity to revolutionize a surgical
team’s capabilities when performing laparoscopic procedures.’’
Leveraging the Performance-Guided Surgery™
framework, the Senhance Surgical System advances clinical
intelligence by providing surgeons with augmented intelligence and
digital tools to perform consistently superior surgery.
Asensus Surgical's technology platform, Senhance Surgical
System, is the first of its kind digital laparoscopic platform that
leverages augmented intelligence to provide unmatched performance
and patient outcomes through machine learning. Senhance goes beyond
the typical surgical robotic systems, providing surgical assurance
through haptic feedback, eye-tracking camera control, and 3D
visualization, and is the first platform to offer 3mm instruments
(the smallest instrument available in the world on a robotic
surgical platform). The Senhance Surgical System is powered by the
Intelligent Surgical Unit™ (ISU™). The ISU enables machine
vision-driven control of the camera for a surgeon by responding to
commands and recognizing certain objects and locations in the
surgical field, and allows a surgeon to change the visualized field
of view using the movement of their instruments.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery. This
builds upon the foundation of Digital Laparoscopy with the Senhance
Surgical System powered by the Intelligent Surgical Unit (ISU) to
increase surgeon control and reduce surgical variability. With the
addition of machine vision, augmented intelligence, and deep
learning capabilities throughout the surgical experience, we intend
to holistically address the current clinical, cognitive and
economic shortcomings that drive surgical outcomes and value-based
healthcare. Learn more about Performance-Guided Surgery and Digital
Laparoscopy with the Senhance Surgical System here:
www.senhance.com. Now available for sale in the US, EU, Japan,
Russia, and select other countries. For a complete list of
indications for use, visit: www.senhance.com/indications. For more
information, visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alertsLinkedIn:
https://www.linkedin.com/company/asensus-surgical-incTwitter:
https://twitter.com/AsensusSurgicalYouTube:
https://www.youtube.com/c/transenterixVimeo:
https://vimeo.com/asxc
Forward-Looking Statements
This press release includes statements relating to the Senhance
Surgical System and the sale of a Senhance System to a distribution
partner, which will be ultimately placed at an end user hospital in
the Commonwealth of Independent States. These statements and other
statements regarding our future plans and goals constitute "forward
looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and are intended to qualify for the safe harbor from
liability established by the Private Securities Litigation Reform
Act of 1995. Such statements are subject to risks and uncertainties
that are often difficult to predict, are beyond our control and
which may cause results to differ materially from expectations and
include whether the Senhance Surgical System provides the
opportunity to revolutionize a surgical team’s capabilities when
performing laparoscopic procedures. For a discussion of the risks
and uncertainties associated with the Company’s business, please
review our filings with the Securities and Exchange Commission
(SEC), including our Annual Report on Form 10-K for the year ended
December 31, 2021, filed with the SEC on February 28, 2022 and our
other filings we make with the SEC. You are cautioned not to place
undue reliance on these forward looking statements, which are based
on our expectations as of the date of this press release and speak
only as of the origination date of this press release. We undertake
no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
INVESTOR CONTACT:Mark Klausner or Mike
Vallie443-213-0499invest@asensus.com
MEDIA CONTACT:Lauren Stredler847-271-6891CG
Lifelstredler@cglife.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/24cd4ee5-138f-47e8-b0b0-fd04ebb2844e
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From Sep 2023 to Sep 2024